Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, international, multicenter, open-label, long-term extension study. The
primary objective of this study is to evaluate the long-term safety and tolerability of oral
edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.